Northwest Biotherapeutics (OTCMKTS:NWBO) Stock Crosses Below 200 Day Moving Average - Here's What Happened

Key Points

• Northwest Biotherapeutics shares have dropped below their 200-day moving average for the first time, trading at $0.25, which raises concerns about potential selling pressure.
• The company reported a loss of $0.01 earnings per share for the previous quarter, with quarterly revenue of $0.38 million.
• Northwest Biotherapeutics focuses on developing personalized immune therapies for cancer using its innovative DCVax platform technology.

Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO - Get Free Report) shares crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $0.26 and traded as low as $0.23. Northwest Biotherapeutics shares last traded at $0.25, with a volume of 1,399,658 shares traded.

Northwest Biotherapeutics Stock Performance

The firm has a market capitalization of $366.75 million, a PE ratio of -3.54 and a beta of -1.14. The stock's 50 day simple moving average is $0.25 and its two-hundred day simple moving average is $0.26.

Northwest Biotherapeutics (OTCMKTS:NWBO - Get Free Report) last posted its quarterly earnings results on Thursday, May 15th. The biotechnology company reported ($0.01) EPS for the quarter. The firm had revenue of $0.38 million during the quarter.

Northwest Biotherapeutics Company Profile

Northwest Biotherapeutics, Inc, a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer.